News MBX Biosciences, Inc.

Equities

MBX

US55287L1017

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:56:25 2026-04-15 pm EDT			5-day change	1st Jan Change
32.93 ^USD	+0.37%		+3.70%	+4.09%

Mar. 16	Mbx Biosciences Insider Bought Shares Worth $525,663, According to a Recent SEC Filing	MT
Mar. 12	MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

All News

Apr. 03	MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
Mar. 16	Mbx Biosciences Insider Bought Shares Worth $525,663, According to a Recent SEC Filing	MT
Mar. 12	MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Mar. 12	MBX Biosciences Q4 Net Loss Widens; Expects Cash Runway Into 2029	MT
Mar. 12	Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss	MT
Mar. 12	MBX Biosciences : Company Overview - March 2026	PU
Mar. 12	MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights	AQ
Mar. 10	MBX Biosciences, Inc. Appoints Karen Basbaum As Chief Business Officer	CI
Mar. 10	MBX Biosciences Appoints Karen Basbaum as Chief Business Officer	AQ
Mar. 09	MBX Plans Phase 3 Trial of Hypoparathyroidism Drug in Q3	MT
Mar. 09	MBX Biosciences Announces Phase 3 Development Plan For Once-Weekly Canvuparatide For Hypoparathyroidism	CI
Mar. 09	MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism	AQ
Feb. 27	MBX Biosciences Says CFO to Step Down; Names Interim Finance Chief	MT
Feb. 27	MBX Biosciences, Inc. Announces CFO Changes	CI
Feb. 23	MBX Biosciences to Participate in Upcoming March Investor Conferences	AQ
Feb. 11	MBX Biosciences to Participate in Upcoming Investor Conferences	AQ
Jan. 28	Barclays Initiates Coverage on MBX Biosciences With Overweight Rating	MT
Jan. 22	MBX Biosciences, Inc. Announces Board and Committee Changes	CI
Jan. 22	MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair	AQ
Jan. 14	MBX Biosciences, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03:45 PM
Jan. 13	MBX Biosciences : Company Overview - January 2025	PU
Jan. 11	Mbx Biosciences says phase 3 trial of canvuparatide to start in Q3 2026	RE
Jan. 11	MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference	AQ
Jan. 07	UBS Initiates MBX Biosciences at Buy With $60 Price Target	MT
Dec. 21	MBX Biosciences, Inc.(NasdaqGS:MBX) added to S&P Pharmaceuticals Select Industry Index	CI